A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)

Not Applicable

• Conditions: To assess the efficacy and toxicity of Osimertinib plus ramucirumab

• Registration Number: JPRN-UMIN000030142
• Lead Sponsor: Wakayama Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-28
• Study Completion: 2020-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Not provided

Exclusion Criteria

1) Any history of interstitial pneumonia, or any evidence of interstitial lung disease by CT scan. 2) Not able to swallow tablets. 3) Considered to be high risk of bleeding. 4) The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to first dose of protocol therapy 5) With serious illness or medical condition6) Undergone prior therapy, or procedure within defined period prior to enrollment 7) With local infection that requires procedure, or active systemic infection 8) HBS antigen (+) 9) Leptomeningeal carcinomatosis 10) Concurrent malignancy 11) Pregnant (must be negative serum pregnancy test or repeated urine test within 7 days prior to first dose), breast feeding, childbearing potential at enrollment, or not willing to use adequate contraceptive methods 12) Serious psychiatric condition that is hard to register this study 13) Known history of serious allergy 14) Other reason that the investigator would make the patient ineligible for entry into this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified